IPP Bureau

Biorchestra announces US$45 million series C fundraising
Biorchestra announces US$45 million series C fundraising

By IPP Bureau - February 23, 2022

he financing was significantly oversubscribed with high demand from both existing and new investors.

Vicore advances on new chemical entity from VP03 program
Vicore advances on new chemical entity from VP03 program

By IPP Bureau - February 23, 2022

Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022

Agilent posts Q1 FY2022 revenue at US$ 1.67 billion
Agilent posts Q1 FY2022 revenue at US$ 1.67 billion

By IPP Bureau - February 23, 2022

Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.

Moderna and Thermo Fisher Scientific to deepen mRNA collaboration
Moderna and Thermo Fisher Scientific to deepen mRNA collaboration

By IPP Bureau - February 23, 2022

The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies

WHO establishes biomanufacturing training hub in South Korea
WHO establishes biomanufacturing training hub in South Korea

By IPP Bureau - February 23, 2022

Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub

Merck completes acquisition of biopharma CDMO Exelead
Merck completes acquisition of biopharma CDMO Exelead

By IPP Bureau - February 23, 2022

Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science

Bayer highlights pharma business plans on Media Day
Bayer highlights pharma business plans on Media Day

By IPP Bureau - February 23, 2022

Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)

Sanofi India posts CY2021 PAT at Rs. 944.4 Cr
Sanofi India posts CY2021 PAT at Rs. 944.4 Cr

By IPP Bureau - February 23, 2022

The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.

Biosion appoints Joel Edwards as Chief Business Officer
Biosion appoints Joel Edwards as Chief Business Officer

By IPP Bureau - February 22, 2022

Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.

PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery
PrecisionLife appoints Colin Stubberfield as SVP Drug Discovery

By IPP Bureau - February 22, 2022

He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,

Formulated Solutions appoints John Maddox as COO
Formulated Solutions appoints John Maddox as COO

By IPP Bureau - February 22, 2022

John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida

Daewoong Pharmaceutical posts strong financials in 2021
Daewoong Pharmaceutical posts strong financials in 2021

By IPP Bureau - February 22, 2022

Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.

Prestige BioPharma’s Tuznue receives EU-GMP certification
Prestige BioPharma’s Tuznue receives EU-GMP certification

By IPP Bureau - February 22, 2022

Thermo Scientific offers a new portfolio of chromatography and mass spectrometry consumables
Thermo Scientific offers a new portfolio of chromatography and mass spectrometry consumables

By IPP Bureau - February 22, 2022

The SureSTART consumables portfolio is designed for higher performance requirements, while meeting customer budgets

World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China
World’s first clinical trial for 3D bioprinted stem cell vascular grafts in China

By IPP Bureau - February 22, 2022

Revotek announced that it has received clearance from the National Health Commission of China to begin a clinical study in the West China Hospital, Chengdu, with its first stem cell 3D bioprinting product, REVOVAS.

Latest Stories

Interviews

Packaging